FY2024 EPS Estimates for Eyenovia, Inc. (NASDAQ:EYEN) Increased by Analyst

Eyenovia, Inc. (NASDAQ:EYEN) – Research analysts at Brookline Capital Management lifted their FY2024 earnings per share (EPS) estimates for Eyenovia in a research report issued on Monday, September 30th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($0.47) per share for the year, up from their previous forecast of ($0.49). The consensus estimate for Eyenovia’s current full-year earnings is ($0.57) per share. Brookline Capital Management also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.36) EPS, FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.08) EPS and FY2028 earnings at ($0.02) EPS.

Other research analysts have also recently issued reports about the stock. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research report on Tuesday, August 13th.

Eyenovia Stock Up 2.5 %

EYEN stock opened at $0.48 on Thursday. The company has a current ratio of 0.46, a quick ratio of 0.27 and a debt-to-equity ratio of 3.72. The company’s 50 day moving average is $0.69 and its 200 day moving average is $0.78. The stock has a market cap of $26.00 million, a price-to-earnings ratio of -0.63 and a beta of 1.74. Eyenovia has a 1-year low of $0.37 and a 1-year high of $2.57.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $1.38 million. Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%.

Insiders Place Their Bets

In other news, CEO Michael M. Rowe bought 50,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer now directly owns 82,927 shares in the company, valued at $47,268.39. This represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 7.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EYEN. Leo Wealth LLC bought a new position in shares of Eyenovia in the fourth quarter worth approximately $34,000. BNP Paribas Financial Markets grew its holdings in shares of Eyenovia by 1,444.4% in the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after purchasing an additional 205,390 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after purchasing an additional 360,924 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its holdings in shares of Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Ground Swell Capital LLC bought a new stake in Eyenovia in the second quarter valued at $27,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.